Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 4, 2010, Pages 383-388

  Javsicas, L H ^a,b   Giguere S ^a   Womble, Ariel Y ^a,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b Upstate Equine Medical Center   (United States)

^c University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; TELITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; FOAL; HORSE; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHODOCOCCUS EQUI; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; EPITHELIUM; ERYTHROMYCIN; FEMALE; HORSES; KETOLIDES; LINEAR MODELS; LUNG; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; RHODOCOCCUS EQUI;

RHODOCOCCUS EQUI;

EID: 77954421113     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2009.01151.x     Document Type: Article

References (34)

1. Baldwin, D.R., Honeybourne, D. Wise, R. (1992) Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrobial Agents and Chemotherapy, 36, 1171 1175.
2. Brinker, A.D., Wassel, R.T., Lyndly, J., Serrano, J., Avigan, M., Lee, W.M. Seeff, L.B. (2009) telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology, 49, 250 257.
3. Cantalloube, C., Bhargava, V., Sultan, E., Vacheron, F., Batista, I. Montay, G. (2003) Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. International Journal of Antimicrobial Agents, 22, 112 121.
4. Chen, Y., Guo, J.J., Healy, D.P., Lin, X. Patel, N.C. (2008) Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Annals of Pharmacotherapy, 42, 1791 1796.
5. Clinical and Laboratory Standard Institute (2008) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals Approved standards, CLSI document M31-A3
6. Clinical and Laboratory Standard Institute (2009) Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement, CLSI document M100-S19
7. Conte, J.E., Golden, J., Duncan, S., McKenna, E., Lin, E. Zurlinden, E. (1996) Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrobial Agents and Chemotherapy, 40, 1617 1622.
8. Drusano, G.L. (2005) Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy, 25, 150S 158S.
9. Fietta, A., Merlini, C. Gialdroni, G.G. (1997) Inhibition of intracellular growth of staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. Journal of Chemotherapy, 9, 17 22.
10. Gibaldi, M. Perrier, D. (1982) Non-compartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd edn. Eds Gibaldi, M. Perrier, D, pp. 409 417. Marcel Dekker
11. Giguère, S., Jacks, S., Roberts, G.D., Hernandez, J., Long, M.T. Ellis, C. (2004) Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi Pneumonia. Journal of Veterinary Internal Medicine, 18, 568 573.
12. Giguère, S., Lee, E., Williams, E., Cohen, N.D., Chaffin, M.K., Halbert, N., Martens, R.J., Franklin, R.P., Clark, C. Slovis, N.M. (2009) Prevalence of Rhodococcus equi isolates resistant to macrolides or rifampin and outcome of infected foals. Journal of the American Veterinary Medical Association. In press.
13. Hillidge, C.J. (1987) Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Veterinary Microbiology, 14, 337 342.
14. Jacks, S., Giguère, S., Gronwall, P.R., Brown, M.P. Merritt, K.A. (2001) Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. American Journal of Veterinary Research, 62, 1870 1875.
15. Jacks, S., Giguère, S., Gronwall, R.R., Brown, M.P. Merritt, K.A. (2002) Disposition of oral clarithromycin in foals. Journal of Veterinary Pharmacology and Therapeutics, 25, 359 362.
16. Jacks, S., Giguère, S. Nguyen, A. (2003) In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin and 20 other antimicrobials. Antimicrobial Agents Chemotherapy, 47, 1742 1745.
17. Kenney, D.G., Robbins, S.C., Prescott, J.F., Kaushik, A. Baird, J.D. (1994) Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Equine Veterinary Journal, 26, 246 248.
18. Khair, O.A., Andrews, J.M., Honeybourne, D., Jevons, G., Vacheron, F. Wise, R. (2001) Lung concentrations of telithromycin after oral dosing. Journal of Antimicrobial Chemotherapy, 47, 837 840.
19. Kikuchi, J., Yamazaki, K., Kikuchi, E., Ishizaka, A. Nishimura, M. (2007) Pharmacokinetics of telithromycin using bronchoscopic microsampling after single and multiple oral doses. Pulmonary Pharmacology and Therapeutics, 20, 549 555.
20. Labro, M.T. (1996) Intracellular bioactivity of macrolides. Clinical Microbiology of Infection, 1 (Suppl 1 S24 S30.
21. Lodise, T.P., Preston, S., Bhargava, V., Bryskier, A., Nusrat, R., Chapel, S., Rangaraju, M. Drusano, G.L. (2005) Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagnostic Microbiology and Infectious Disease, 52, 45 52.
22. Mandell, G.L. Coleman, E. (2001) Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrobial Agents and Chemotherapy, 45, 1794 1798.
23. Namour, F., Wessels, D.H., Pascual, M.H., Reynolds, D., Sultan, E. Lenfant, B. (2001) Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrobial Agents and Chemotherapy, 45, 170 175.
24. Prescott, J.F. (1981) The susceptibility of isolates of Corynebacterium equi to antimicrobial drugs. Journal of Veterinary Pharmacology and Therapeutics, 4, 27 31.
25. Reinert, R.R. Al-Lahham, A. (2005) Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae isolates with 23s rRNA mutations and changes in ribosomal proteins L4 and L22. Antimicrobial Agents and Chemotherapy, 49, 3011 3013.
26. Rennard, S.I., Basset, G., Lecossier, D., O'Donnell, K.M., Pinkston, P., Martin, P.G. Crystal, R.G. (1986) Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. Journal of Applied Physiology, 60, 532 538.
27. Retsema, J.A., Bergeron, J.M., Girard, D., Milisen, W.B. Girard, A.E. (1993) Preferential concentration of azithromycin in an infected mouse thigh model. Journal of antimicrobial Chemotherapy, 31 (Suppl E 5 16.
28. Shi, J., Montay, G. Bhargava, V.O. (2005) Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clinical Pharmacokinetics, 44, 915 934.
29. Soriano, F., Fernandez-Roblas, R., Calvo, R., Garcia-Calvo, G., Pardeiro, M. Bryskier, A. (1998) In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens. Journal of Antimicrobial Chemotherapy, 42, 647 649.
30. Suarez-Mier, G., Giguère, S. Lee, E.A. (2007) Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals. Journal of Veterinary Pharmacology and Therapeutics, 30, 109 115.
31. Sweeney, C.R., Sweeney, R.W. Divers, T.J. (1987) Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy. Veterinary Microbiology, 14, 329 336.
32. Tessier, P.R., Mattoes, H.M., Dandekar, P.K., Nightingale, C.H. Nicolau, D.P. (2005) Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrobial Agents and Chemotherapy, 49, 188 194.
33. Zeitlinger, M., Wagner, C.C. Heinisch, B. (2009) Ketolides - the modern relatives of macrolides : the pharmacokinetic perspective. Clinical Pharmacokinetics, 48, 23 38.
34. Zhanel, G.G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A. Hoban, D.J. (2005) Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (MefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrobial Agents and Chemotherapy, 49, 1943 1948.